From the Editors
Here's what to expect from the February issue of The Oncology Pharmacist.
In the October issue of The Oncology Pharmacist, we feature highlights from the recent Hematology/Oncology Pharmacy Association (HOPA)’s Oncology Pharmacy Practice Management Program, including an article on the challenges of managing patients with non–small-cell lung cancer (NSCLC) associated with ALK mutations. At HOPA, Jim M. Koeller, MS, Professor, College of Pharmacy, The University of Texas at Austin, discussed the current treatment guidelines for this patient population, emphasizing the need for pharmacist inclusion during testing for ALK mutations.
In this issue of The Oncology Pharmacist, we feature an article on the new—and often misunderstood—world of biosimilars
In the May issue of The Oncology Pharmacist, we feature a recent study that was presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium on the association between prophylactic gabapentin, weight loss, and narcotic dependency in patients with oropharyngeal cancer undergoing radiation therapy.
In the February issue of The Oncology Pharmacist, we feature a recent study that was presented at the 2015 Palliative Care in Oncology Symposium on aprepitant (Emend), a centrally acting neurokinin-1 antagonist indicated for patients with chemotherapy-induced nausea and vomiting.
In the November issue of The Oncology Pharmacist, we provide a highlight of a recent study that was presented at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer on the use of docetaxel plus nintedanib in patients with non–small-cell lung cancer (NSCLC)
In this month’s issue of The Oncology Pharmacist, we present coverage of the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer. We highlight presentations on the effectiveness of rolapitant for chemotherapy-induced nausea and vomiting, as well as data on the association between osteonecrosis of the jaw and medication.
In this month’s issue ofThe Oncology Pharmacist (TOP), we present our coverage of the news from the 11th annual Hematology/Oncology Pharmacy Association (HOPA) conference. TOP was there, and we highlight presentations about the role of pharmacists in hospice and palliative care, the disposal of oral cancer drugs, and opportunities in survivorship care.
In its eighth year, The Oncology Pharmacist (TOP) will continue to provide oncology pharmacists and their colleagues with the latest research findings and results of large clinical trials, interviews with thought leaders, as well as content for pharmacy students and residents, and articles on practice management.
The Jefferson School of Pharmacy at Thomas Jefferson University was founded in 2008 and offers an innovative doctor of pharmacy program that prepares graduates for interesting and challenging pharmacy practice roles across the healthcare continuum.
